Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Preclinical/no trial
- ChEMBL max phase
- 2 / 4 (development scale, not regulatory approval)
- Synonyms
- Bucladesina; Bucladesine; Dibutyryl camp; DT-5621; NSC-143108
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseChemical/toxinAlbino Swissmaletopical application to the earbucladesine cream 0.5% or 1.5%, 10 +/- 1 mg cream per ear;…3 h before arachidonic acid challenge for the creams and 60 min before challeng…
Model: arachidonic acid induced acute ear oedema, 20 microlitres of 5% arachidonic acid in acetone applied to the left ear with acetone alone to the right ear
The 1.5% cream reduced ear swelling by 28% after a single application and 24% after two applications, while the 0.5% cream and the 5% solution did not reach significance. Ketoprofen 2.5% gel nearly abolished swelling.
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.